Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

Kanghua Biological, a China-based vaccine provider backed by clinical services provider Tigermed and leather product supplier Aokang, raised almost RM1.06bn ($149m) in its initial public offering, DealStreetAsia has reported. The offering consisted of 15 million shares issued on the Shenzhen Stock Exchange’s ChiNext board and priced at RMB70.37 each. Minsheng Securities is the lead underwriter…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.